Arena Pharma says cannabinoid receptor-targeting olorinab could help treat the pain associated with Crohn’s disease.

The biotech changed its plans because its phase 3 overall response rate data “were not sufficiently mature to conduct the analysis.”

The phase 2 trial linked the Nrf2 activator to improvements in estimated glomerular filtration rate, a measure of kidney damage.

The trade war between the U.S. and China has grown, with tariffs now reaching over $4.75 billion in U.S. medical device exports to the country.

AzurRx Biopharma's lead asset, a recombinant lipase designed to treat a condition linked to chronic pancreatitis, met its endpoints in a phase 2a trial.

Cynata Therapeutics found that mesenchymal stem cells can mute severe immune reactions to CAR-T treatments.

Akcea reported topline data showing its hyperlipoproteinemia drug lowered lipoprotein(a) levels in a phase 2 study in patients with cardiovascular disease.

AnaptysBio has positive data for its lead drug etokimab in a third indication, adding asthma to earlier wins in peanut allergy and atopic dermatitis.